Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000234 · ClinicalTrials.gov registry record · Phase 2
Alternate Day Buprenorphine Administration, Phase XI - 16
A Phase 2 study, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00000234: Completed Phase 2 study, sponsored by University of Vermont.
NCT00000234 is a Phase 2 study that has completed, run by University of Vermont. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000234, a Phase 2 study, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to evaluate open buprenorphine dosing with dose choice after open exposure.
Interventions
- DRUG Buprenorphine
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00000234 record still lists
NCT00000234 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Buprenorphine is the first listed.
NCT00000234 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000234 about?
NCT00000234 is a clinical study titled "Alternate Day Buprenorphine Administration, Phase XI - 16". The purpose of this study is to evaluate open buprenorphine dosing with dose choice after open exposure.
What is the current status of trial NCT00000234?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00000234?
The interventions under investigation include: Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT00000234?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.